头孢哌酮/舒巴坦对鲍氏不动杆菌体外抗菌特性的研究

目的 了解鲍氏不动杆菌的耐药现状及其对头孢哌酮/舒巴坦的耐药特性,为抗菌药物的选用提供依据.方法 回顾性调查2007-2011年每年1-5月分离的鲍氏不动杆菌临床分布情况;应用VITEK-60全自动微生物分析仪检测鲍氏不动杆菌对常用抗菌药物的耐药性,琼脂稀释法检测头孢哌酮/舒巴坦的最低抑菌浓度(MIC).结果 603株鲍氏不动杆菌主要来源于呼吸道标本,占90.4％,且主要集中于几个重症监护病区,占70.3％;除头孢哌酮/舒巴坦外,鲍氏不动杆菌对其他临床常用抗菌药物的耐药性率均＞60.0％,而头孢哌酮/舒巴坦非耐药株中,近年来处于中介的比例＞50.0％.结论 鲍氏不动杆菌临床分离株的标本来源和病区分布均有明显集中趋势,其临床常用抗菌药物耐药严重,头孢哌酮/舒巴坦非耐药株的MIC值明显增高,需引起关注.

Study on in vitro resistance of cefoperazone/sulbactam against Acinetobacter baumannii

OBJECTIVE To investigate the drug resistance of Acinetobacter baumannii and to evaluate the characteristic of resistance against cefoperazone/sulbactam.METHODS Retrospective survey was used to study the distribution of A.baumannii in our hospital from Jan.2007 to May.2011;VITEK-60 AMS was used to detect the susceptibility of A.baumannii against ciprofloxacin,ceftriaxone,ceftazidime,gentamicin,tobramycin,SMZ-TMP,ampicillin/sulbactam,piperacillin/tazobactam and imipenem.Agar dilution method was used to detect the minimum inhibitory concentration(MIC) of cefoperazone/sulbactam.RESULTS A total of 603 strains of A.baumannii were isolated from respiratory tract,accounting for 90.4% and the most risky area was intensive care unit(70.3%).The resistance rate of A.baumannii exceeded 60.0% against clinical frequently used antibiotics except for cefoperazone/sulbactam.The ratio of intermediate exceed 50.0% in cefoperazone/sulbactam un-resistant strains.CONCLUSION A.baumannii tends to distribute in some common sites and comes from the same sources,The drug resistance of A.baumannii is high.The MIC is increasing of strains un-resistant to cefoperazone/sulbactam.